Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting

Advances in Therapy

Volumn 30, Issue 5, 2013, Pages 517-527

  Blume, Steven W ^a   Fox, Kathleen M ^b   Joseph, George ^c   Chuang, Chien Chia ^a   Thomas, Jessy ^c   Gandra, Shravanthi R ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Strategic Healthcare Solutions LLC   (United States)

^c AMGEN INC   (United States)

Author keywords

Adalimumab; Dose escalation; Etanercept; Pharmacy benefit management; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG PROGRAM; DRUG UTILIZATION; FEMALE; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; MALE; PHARMACY BENEFIT MANAGEMENT; PRESCRIPTION; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84879238854     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0034-3     Document Type: Article

References (24)

1. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of non-biologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-84.
2. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005;72:1037-47.
3. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625-39.
4. Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm. 2011;17:S14-8.
5. Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ. 2012;15:264-75.
6. Enbrel® (etanercept) prescribing information. Immunex Corporation, Thousand Oaks, CA. 2011.
7. Humira® (adalimumab) prescribing information. Abbott Laboratories, North Chicago, IL. 2011.
8. Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther. 2008;30:1939-55.
9. Ollendorf DA, Massarotti E, Birbara C, Burgess SM. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm. 2005;11:383-93.
10. Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther. 2009;31:825-35.
11. Huang X, Gu NY, Fox KM, Harrison DJ, Globe D. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin. 2010;26:1637-45.
12. Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health Syst Pharm. 2010;67:1281-7.
13. Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol. 2011;29:26-34.
14. Punzi L, Matucci Cerinic M, Cantini F, et al. Treatment patterns of anti-TNF agents in Italy: an observational study. Reumatismo. 2011;63:18-28.
15. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711-5.
16. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin. 2007;23:1749-59.
17. Bonafede MM, Gandra SR, Fox KM, Wilson KL. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. J Med Econ. 2012;15:635-43.
18. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 2003;9:S136-43.
19. Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2004;5:36.
20. Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface. 2006;19:47-53.
21. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin. 2008;24:2229-40.
22. Gu NY, Huang X, Fox KM, Patel VD, Baumgartner SW, Chiou C-F. Claims data analysis of dosing and cost of TNF antagonist. Am J Pharm Benefits. 2010;2:351-9.
23. Khanna D, Cyhaniuk A, Bedenbaugh A. Use of TNF-inhibitors in the US: utilisation patterns and dose escalation from a representative US rheumatoid arthritis (RA) population. Ann Rheum Dis. 2011;70(Supple 3):197.
24. First DataBank. AnalySource® Online. Wholesale Acquisition Cost (WAC). [Accessed November 13, 2012.] Available from: http://www.fdbhealth.com/ fdb-medknowledge-drug-pricing.